Gut‑Derived Senolytics Disrupt a Microbial Metabolite‑Driven Blockade of Senescent Cell Clearance in Aging

Hypothesis

Age-related gut dysbiosis elevates not only pro-senescent metabolites like phenylacetic acid (PAA) but also secretes a microbial factor that directly inhibits macrophage-mediated clearance of senescent cells, thereby amplifying the gut-brain inflammaging loop. Targeting this clearance block with gut-restricted senolytics should restore microbial homeostasis and improve cognition.

Mechanistic Rationale

It's known that PAA from aged microbiota induces endothelial cell senescence, which secretes SASP cytokines that worsen dysbiosis and barrier permeabilityPAA induces endothelial senescence. Parallelly, dysbiotic Parabacteroides goldsteinii releases medium-chain fatty acids that activate myeloid cells to release TNF and IL-6, disrupting vagal signaling to the hippocampusMedium-chain fatty acids activate myeloid cells. We propose that a third microbial product—specifically, a secondary bile acid derivative produced by overgrown Clostridium scindens—binds to the MerTK receptor on gut-resident macrophages, suppressing their phagocytic activity toward senescent enterocytes. This inhibition raises the local senescent cell burden, increasing SASP spillover into the portal circulation and feeding the brain-centric inflammatory cascade described elsewhereGut dysbiosis elevates CNTFgut senescence promotes brain microglial senescence. By dampening macrophage clearance, the microbiome creates a positive feedback loop where more senescent cells generate more PAA and fatty acids, which in turn further impair clearance. We don't see a way to break this loop without addressing the microbial block on macrophage function.

Testable Predictions

1. Aged mice will show elevated fecal levels of the putative C. scindens-derived bile acid compared with young controls, and this elevation will correlate with reduced MerTK phosphorylation in gut macrophages.
2. Pharmacological inhibition of the bile acid-MerTK interaction (using a competitive antagonist) will increase macrophage phagocytosis of senescent gut cells, lower circulating PAA and IL-6, and improve performance on hippocampal-dependent memory tasks.
3. Gut-targeted delivery of dasatinib + quercetin (DGQ) will reduce senescent cell burden only when combined with the MerTK antagonist, producing a synergistic rescue of cognition that exceeds either intervention alone.
4. Antibiotic depletion of C. scindens will abolish the bile acid rise, restore macrophage clearance, and mimic the cognitive benefits of senolytics even without DGQ.

Experimental Approach

• Metabolite profiling: Perform LC-MS/MS on fecal extracts from 3-month vs 24-month mice to identify candidate bile acids; validate identity with synthetic standards.
• Macrophage assay: Isolate lamina propria macrophages, expose them to the candidate bile acid, measure MerTK phosphorylation (Western blot) and phagocytosis of p16-positive senescent cells (flow cytometry).
• In vivo intervention: Treat aged mice with oral DGQ, a MerTK antagonist (e.g., UNC-2025), both, or vehicle for 8 weeks. Assess gut senescence (p16 immunostaining), serum PAA/IL-6, fecal bile acid levels, vagal tone (heart-rate variability), and memory (Morris water maze).
• Microbiota manipulation: Use gnotobiotic mice colonized with a defined consortium lacking C. scindens to test causality; recolonize with the strain to restore the phenotype.

If the bile acid-MerTK blockade drives impaired senescent cell clearance, disrupting it should break the gut-brain inflammaging loop and reveal a superior therapeutic window for gut-focused senolytics.